Christophe Jean Sells Shares of Rhythm Pharmaceuticals

Christophe Jean, a key figure at Rhythm Pharmaceuticals, Inc., sold 4,712 shares of the company on June 23, 2026. This transaction took place as shares of Rhythm Pharmaceuticals, trading under the ticker RYTM on the NasdaqGM, were priced around $107.55 on Friday.

Insider Buying and Selling at Rhythm Pharmaceuticals, Inc.

Christophe Jean's recent sale of 4,712 shares was not part of a pre-planned trading arrangement. While Jean reduced his holdings, other insiders were active as well. On June 24, 2026, several insiders including Jennifer Good, Stuart Arbuckle, and David McGirr acquired shares, with each purchasing between 2,324 and 3,691 shares.

Other Institutional Activity in Rhythm Pharmaceuticals

Several institutional investors have adjusted their positions in Rhythm Pharmaceuticals recently. Vanguard Portfolio Management LLC opened a new position with 3,040,718 shares valued at approximately $264.45 million. Similarly, Vanguard Capital Management LLC also initiated a new stake with 2,967,825 shares worth about $258.11 million. Meanwhile, BlackRock, Inc. trimmed its holdings by 60,183 shares, bringing its total to 6,237,151 shares valued at $542.45 million. RA Capital Management, L.P. maintained its position with 6,666,837 shares, valued at around $579.81 million.

Rhythm Pharmaceuticals, Inc. Stock Up 0.4%

Rhythm Pharmaceuticals, Inc. has a market capitalization of approximately $6.95 billion. The company's stock has fluctuated between a 52-week low of $60.8 and a high of $122.2. The stock's 50-day moving average is $88.36, while the 200-day moving average stands at $97.77. Rhythm Pharmaceuticals is not currently profitable, as indicated by its forward P/E ratio of -136.76. The company has a beta of 1.923, suggesting it is more volatile than the market.

Analysts Set New Price Targets

Analysts have been active in setting price targets for Rhythm Pharmaceuticals. On June 16, 2026, Canaccord Genuity maintained its buy rating with a price target of $151. Wells Fargo also upheld its buy rating with a target of $155 on June 15, 2026. The consensus among analysts is a strong buy, with an average target price of $139.47 based on 15 opinions.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company based in Boston, Massachusetts. It focuses on developing treatments for rare neuroendocrine diseases. The company's lead product, IMCIVREE (setmelanotide), targets several rare forms of obesity linked to genetic deficiencies. Rhythm is also working on other treatments in various stages of clinical trials, including bivamelagon and RM-718, aimed at addressing MC4R pathway diseases and hypothalamic obesity, respectively. The company is led by CEO Dr. David P. Meeker and employs around 414 people.

Bottom Line

The recent insider sale by Christophe Jean is part of ongoing trading activities by insiders at Rhythm Pharmaceuticals. Investors closely monitor these trades for insights into management's confidence in the company. It's important to remember that insider transactions are reported after they occur and may not reflect current positions. With a strong buy consensus from analysts and active institutional interest, Rhythm Pharmaceuticals remains a company to watch in the biotechnology sector.